4.8 Review

Cracking the ENCODE: From transcription to therapeutics

期刊

HEPATOLOGY
卷 57, 期 6, 页码 2532-2535

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1002/hep.26449

关键词

-

向作者/读者索取更多资源

The human genome encodes the blueprint of life, but the function of the vast majority of its nearly three billion bases is unknown. The Encyclopedia of DNA Elements (ENCODE) project has systematically mapped regions of transcription, transcription factor association, chromatin structure and histone modification. These data enabled us to assign biochemical functions for 80% of the genome, in particular outside of the well-studied protein-coding regions. Many discovered candidate regulatory elements are physically associated with one another and with expressed genes, providing new insights into the mechanisms of gene regulation. The newly identified elements also show a statistical correspondence to sequence variants linked to human disease, and can thereby guide interpretation of this variation. Overall, the project provides new insights into the organization and regulation of our genes and genome, and is an expansive resource of functional annotations for biomedical research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation

Sofia Monteiro, Josephine Grandt, Frank Erhard Uschner, Nina Kimer, Jan Lysgard Madsen, Robert Schierwagen, Sabine Klein, Christoph Welsch, Liliana Schafer, Christian Jansen, Joan Claria, Jose Alcaraz-Quiles, Vicente Arroyo, Richard Moreau, Javier Fernandez, Flemming Bendtsen, Gautam Mehta, Lise Lotte Gluud, Soren Moller, Michael Praktiknjo, Jonel Trebicka

Summary: Systemic inflammation predisposes acutely decompensated cirrhosis to acute-on-chronic liver failure (ACLF). Different inflammasome activations are involved in ACLF development in compensated and recompensated patients. IL-1 alpha and IL-1 beta may serve as independent predictors of ACLF development in compensated and recompensated patients.
Letter Gastroenterology & Hepatology

SARS-CoV-2: Is the liver merely a bystander to severe disease?

Mansoor N. Bangash, Jaimin M. Patel, Dhruv Parekh, Nicholas Murphy, Rachel M. Brown, Ahmed M. Elsharkawy, Gautam Mehta, Matthew J. Armstrong, Desley Neil

JOURNAL OF HEPATOLOGY (2020)

Editorial Material Gastroenterology & Hepatology

The Alter Ego of Albumin in Cirrhosis

Gautam Mehta, Rajiv Jalan

HEPATOLOGY (2021)

Letter Gastroenterology & Hepatology

Defining the prognosis of critically ill patients with alcohol-related liver disease

Su Lin, Banwari Agarwal, Rahul Kumar, Rajiv Jalan, Gautam Mehta

JOURNAL OF HEPATOLOGY (2021)

Review Gastroenterology & Hepatology

Management of the major complications of cirrhosis: Beyond guidelines

Juan Carlos Garcia-Pagan, Claire Francoz, Sara Montagnese, Marco Senzolo, Rajeshwar P. Mookerjee

Summary: With a growing understanding of the pathophysiology of cirrhosis and its complications, new therapies and management strategies have emerged in recent years. While many advances have helped inform current guidelines on managing key complications of cirrhosis, there are still areas where evidence is lacking or opinions are divided among practitioners. This section explores some of these controversial areas, presenting evidence for suggested management approaches beyond existing guidelines.

JOURNAL OF HEPATOLOGY (2021)

Editorial Material Gastroenterology & Hepatology

Editorial: biomarkers for alcohol-related liver fibrosis-almost there?

Shilpa Chokshi, Gautam Mehta

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Article Multidisciplinary Sciences

Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study

Nathanael Fillmore, Steven Bell, Ciyue Shen, Vinh Nguyen, Jennifer La, Maureen Dubreuil, Judith Strymish, Mary Brophy, Gautam Mehta, Hao Wu, Judy Lieberman, Nhan Do, Chris Sander

Summary: The study suggests that Disulfiram may reduce the risk of SARS-CoV-2 infection and severity of COVID-19. Further clinical trials are needed to assess its therapeutic effects.

PLOS ONE (2021)

Article Multidisciplinary Sciences

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

Caroline Junqueira, Angela Crespo, Shahin Ranjbar, Luna B. de Lacerda, Mercedes Lewandrowski, Jacob Ingber, Blair Parry, Sagi Ravid, Sarah Clark, Marie Rose Schrimpf, Felicia Ho, Caroline Beakes, Justin Margolin, Nicole Russell, Kyle Kays, Julie Boucau, Upasana Das Adhikari, Setu M. Vora, Valerie Leger, Lee Gehrke, Lauren A. Henderson, Erin Janssen, Douglas Kwon, Chris Sander, Jonathan Abraham, Marcia B. Goldberg, Hao Wu, Gautam Mehta, Steven Bell, Anne E. Goldfeld, Michael R. Filbin, Judy Lieberman

Summary: This study suggests that SARS-CoV-2 infection in monocytes and macrophages, mediated by antibody uptake, triggers inflammatory cell death and systemic inflammation, which prevents the production of infectious virus but contributes to COVID-19 pathogenesis.

NATURE (2022)

Review Biochemistry & Molecular Biology

Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence

Anne Catrine Daugaard Mikkelsen, Kristoffer Kjaergaard, Rajeshwar Prosad Mookerjee, Hendrik Vilstrup, Gregers Wegener, Cecilie Bay-Richter, Karen Louise Thomsen

Summary: Non-alcoholic fatty liver disease (NAFLD) is associated with cognitive impairment, affecting memory, attention, and daily activities. The neurobiological changes in preclinical models of NAFLD include neuroinflammation, neurodegeneration, neurotransmitter alterations, oxidative stress, and changes in proteins and synaptic density. This systematic review supports the association between NAFLD and neurobiological changes in all stages.

NEUROCHEMICAL RESEARCH (2022)

Review Gastroenterology & Hepatology

SARS-CoV-2 infection and liver involvement

Mingjia Luo, Maria Pilar Ballester, Ugo Soffientini, Rajiv Jalan, Gautam Mehta

Summary: The COVID-19 pandemic has significantly affected patients with underlying liver disease, causing high morbidity and mortality. The mechanisms of liver injury in SARS-CoV-2 infection are not fully understood, but elevated liver enzymes have been identified as risk factors. This review provides an overview of the impact of COVID-19 on various liver diseases, including cirrhosis, alcohol-related liver disease, autoimmune liver disease, non-alcoholic fatty liver disease, hepatitis B and C virus infection, liver-transplant recipients, and hepatocellular carcinoma. Additionally, emerging data on vaccination in liver diseases are discussed.

HEPATOLOGY INTERNATIONAL (2022)

Article Gastroenterology & Hepatology

Evaluation of CirrhoCare® - a digital health solution for home management of individuals with cirrhosis

Konstantin Kazankov, Simone Novelli, Devnandan A. Chatterjee, Alexandra Phillips, Anu Balaji, Maruthi Raja, Graham Foster, Dhiraj Tripathi, Ravan Boddu, Ravi Kumar, Rajiv Jalan, Rajeshwar P. Mookerjee

Summary: This study aimed to assess the feasibility and potential clinical benefits of remote management using CirrhoCare (R) for individuals with acutely decompensated cirrhosis. The results showed that individuals managed with CirrhoCare (R) had lower risk of re-decompensation, fewer readmissions, and shorter hospital stays. This approach warrants further investigation in larger controlled clinical trials.

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Guidance document: risk assessment of patients with cirrhosis prior to elective non-hepatic surgery

Nadir Abbas, Jonathan Fallowfield, David Patch, Adrian J. Stanley, Raj Mookerjee, Emmanouil Tsochatzis, Joanna A. Leithead, Peter Hayes, Abhishek Chauhan, Vikram Sharma, Neil Rajoriya, Simon Bach, Thomas Faulkner, Dhiraj Tripathi

Summary: Due to the increasing incidence of cirrhosis in the UK, more patients with chronic liver disease are being considered for non-hepatic surgery. Although there was a historical reluctance to offer surgery to these patients, careful risk assessment has shown that selected patients with compensated early-stage cirrhosis can have good outcomes. However, there are well-known risks associated with surgery in these patients, such as general anesthesia, bleeding, infections, impaired wound healing, acute kidney injury, and cardiovascular compromise.

FRONTLINE GASTROENTEROLOGY (2023)

Review Gastroenterology & Hepatology

Vaccination in liver diseases and liver transplantation: Recommendations, implications and opportunities in the post-COVID era

Maria Pilar Ballester, Rajiv Jalan, Gautam Mehta

Summary: Interest in vaccination efficacy and toxicity has increased due to the COVID-19 pandemic. Patients with chronic liver disease and liver transplant recipients may have suboptimal immune responses to vaccines, making them more susceptible to vaccine-preventable infections. The pandemic has accelerated the development of vaccination technology, which will benefit patients with liver disease. This review aims to discuss the impact of vaccine-preventable infections on these patients, evaluate current vaccination strategies, and provide insights into recent developments.

JHEP REPORTS (2023)

Review Gastroenterology & Hepatology

Mechanisms and treatment approaches for ACLF

Salvatore Piano, Nadim Mahmud, Paolo Caraceni, Marta Tonon, Rajeshwar Prosad Mookerjee

Summary: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome characterized by decompensation of cirrhosis, severe systemic inflammation and organ failures. It is often triggered by intra- and/or extrahepatic insults such as bacterial infections or alcohol-related hepatitis. The management of ACLF includes supporting organ failures, treating precipitating factors, and considering liver transplantation in severe cases.

LIVER INTERNATIONAL (2023)

Article Biochemical Research Methods

A permeability assay for mouse intestinal organoids

Stijn Aaron den Daas, Ugo Soffientini, Shilpa Chokshi, Gautam Mehta

Summary: In this study, an assay for measuring intestinal permeability in mouse intestinal organoids is described. The passage of propidium iodide (PI) within the organoid lumen is used as an indicator of tight junction disruption or epithelial cell death. This technique allows for the analysis of insults, toxins, or treatments on intestinal organoid permeability.

STAR PROTOCOLS (2022)

暂无数据